Pasar al contenido principal
Toggle navigation
Menú
Overall search
Search ClinicalINFO
En afiliación con
HIV.gov
Buscar
Cerrar
Main navigation
Inicio
Sobre Clinicalinfo
Guías
Medicamentos
Glosario
Noticias
Recursos
Contáctenos
Español (Spanish)
Toggle Dropdown
Español (Spanish)
English
Inicio
Search Results
Overall search
Search ClinicalINFO
Search Results
681 – 700
of
3979
Dosing Recommendations for Prevention and Treatment of Malaria
https://clinicalinfo.hiv.gov/node/11143
Table 1. Primary Prophylaxis of Opportunistic Infections in Children with and Exposed to HIV— Summary of Recommendations
https://clinicalinfo.hiv.gov/node/11144
Table 2. Secondary Prophylaxis of Opportunistic Infections in Children with and Exposed to HIV — Summary of Recommendations
https://clinicalinfo.hiv.gov/node/11145
Table 3. Treatment of Opportunistic Infections in Children with and Exposed to HIV — Summary of Recommendations
https://clinicalinfo.hiv.gov/node/11146
Table 4. Common Drugs Used for Treatment of Opportunistic Infections in HIV-Infected Children: Preparations and Major Toxicities
https://clinicalinfo.hiv.gov/node/11147
Table 5. HIV-Related Laboratory Monitoring Schedule for Pregnant People With HIV
https://clinicalinfo.hiv.gov/node/11148
Table 14. Antiretroviral Drug Use in Pregnant People With HIV: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy
https://clinicalinfo.hiv.gov/node/11149
Supplemental Table 1. Results of Major Studies on Antiretroviral Interventions to Prevent Perinatal HIV Transmission
https://clinicalinfo.hiv.gov/node/11150
Appendix C. Clinical Trial Efficacy Data for Daily, Oral Tenofovir Disoproxil Fumarate/Emtricitabine as Pre-Exposure Prophylaxis
https://clinicalinfo.hiv.gov/node/11151
Raltegravir
https://clinicalinfo.hiv.gov/node/11153
Table A. Summary of IMPAACT P1066 Cohorts and Participation
https://clinicalinfo.hiv.gov/node/11154
Table B. Raltegravir Pharmacokinetic Parameters for Raltegravir-Naive and Raltegravir-Exposed Neonates
https://clinicalinfo.hiv.gov/node/11155
Table 6. Sample Schedule for Clinical and Laboratory Monitoring of Children Before and After Initiation of Antiretroviral Therapy<sup>a</sup>
https://clinicalinfo.hiv.gov/node/11156
Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity
https://clinicalinfo.hiv.gov/node/11157
Table 17b. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Dyslipidemia
https://clinicalinfo.hiv.gov/node/11158
Table 17c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects
https://clinicalinfo.hiv.gov/node/11159
Table 17d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects
https://clinicalinfo.hiv.gov/node/11160
Table 17e. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hepatic Events
https://clinicalinfo.hiv.gov/node/11161
Table 17f. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus
https://clinicalinfo.hiv.gov/node/11162
Table 17g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis
https://clinicalinfo.hiv.gov/node/11163
Paginación
Primera página
«
Página anterior
‹
…
Página
31
Página
32
Página
33
Página
34
Página actual
35
Página
36
Página
37
Página
38
Página
39
…
Siguiente página
›
Última página
»